Two dose levels of a single-administration gene therapy were well-tolerated and led to functional improvements in ambulatory ...

Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercial outlook and spurred debate as to whether ...

Edgewise Therapeutics, Inc.’s EWTX share price has surged by 7.97%, which has investors questioning if this is right time to sell.

Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb are included in this Analyst Blog.

In this article, we are going to take a look at where Edgewise Therapeutics, Inc. (NASDAQ:EWTX) stands against other stocks ...

Market volatility has not dissuaded some insiders from making big share purchases. The most notable transactions came from ...

Shares of Edgewise Therapeutics EWTX plunged 47.7% in a week, likely due to safety concerns for its investigational candidate, EDG-7500, in patients with obstructive or nonobstructive hypertrophic ...

We recently published a list of 10 Unstoppable Stocks That Could Double Your Money. In this article, we are going to take a look at where Edgewise Therapeutics, Inc. (NASDAQ:EWTX) stands against other ...

Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report) had its price target lowered by research analysts at Royal Bank of ...

Piper Sandler reaffirmed their overweight rating on shares of Edgewise Therapeutics (NASDAQ:EWTX – Free Report) in a research ...

The Cirrus-HCM trial is an open-label, four-week study evaluating the efficacy of two dosages (50 mg and 100 mg) of EDG-7500 in patients diagnosed with either obstructive or nonobstructive HCM. The ...

Analyst Price Forecast Suggests 258.92% Upside As of April 2, 2025, the average one-year price target for Edgewise Therapeutics is $48.70/share. The forecasts range from a low of $30.30 to a high ...